LPL Financial’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.45M Buy
135,546
+41,120
+44% +$1.68M ﹤0.01% 2425
2026
Q1
$3.14M Sell
94,426
-2,107
-2% -$62.8K ﹤0.01% 3082
2025
Q4
$2.88M Sell
96,533
-38,046
-28% -$1.24M ﹤0.01% 3052
2025
Q3
$4.86M Sell
134,579
-30,524
-18% -$1.01M ﹤0.01% 2484
2025
Q2
$5.94M Sell
165,103
-19,960
-11% -$743K ﹤0.01% 2175
2025
Q1
$7.3M Buy
185,063
+1
+0% +$34 ﹤0.01% 1839
2024
Q4
$5.57M Buy
185,062
+70,740
+62% +$2.03M ﹤0.01% 1994
2024
Q3
$2.67M Sell
114,322
-18,958
-14% -$414K ﹤0.01% 2458
2024
Q2
$2.37M Buy
133,280
+18,778
+16% +$300K ﹤0.01% 2451
2024
Q1
$1.74M Buy
114,502
+21,934
+24% +$349K ﹤0.01% 2651
2023
Q4
$1.58M Buy
92,568
+1,180
+1% +$13.7K ﹤0.01% 2638
2023
Q3
$764K Buy
91,388
+24,230
+36% +$338K ﹤0.01% 3135
2023
Q2
$1.67M Buy
67,158
+17,010
+34% +$439K ﹤0.01% 2410
2023
Q1
$754K Buy
50,148
+11,293
+29% +$172K ﹤0.01% 2985
2022
Q4
$460K Buy
38,855
+11,480
+42% +$83.3K ﹤0.01% 3328
2022
Q3
$162K Sell
27,375
-1,265
-4% -$8.3K ﹤0.01% 4009
2022
Q2
$122K Sell
28,640
-1,286
-4% -$8.03K ﹤0.01% 4086
2022
Q1
$285K Buy
29,926
+2,632
+10% +$30.5K ﹤0.01% 3598
2021
Q4
$519K Buy
27,294
+461
+2% +$12K ﹤0.01% 3250
2021
Q3
$893K Buy
26,833
+7,476
+39% +$231K ﹤0.01% 2705
2021
Q2
$751K Buy
19,357
+7,909
+69% +$311K ﹤0.01% 2808
2021
Q1
$552K Sell
11,448
-8,936
-44% -$429K ﹤0.01% 2941
2020
Q4
$1.06M Buy
20,384
+5,999
+42% +$203K ﹤0.01% 2135
2020
Q3
$385K Buy
14,385
+81
+0.6% +$1.86K ﹤0.01% 2697
2020
Q2
$279K Buy
14,304
+985
+7% +$15.9K ﹤0.01% 2889
2020
Q1
$131K Sell
13,319
-677
-5% -$8.55K ﹤0.01% 2935
2019
Q4
$155K Buy
13,996
+2,233
+19% +$17K ﹤0.01% 3159
2019
Q3
$66K Sell
11,763
-175
-1% -$1.22K ﹤0.01% 3190
2019
Q2
$103K Buy
11,938
+309
+3% +$2.34K ﹤0.01% 3150
2019
Q1
$93K Sell
11,629
-283
-2% -$1.53K ﹤0.01% 3077
2018
Q4
$49K Buy
+11,912
New +$59.2K ﹤0.01% 3006

Other funds holding TGTX

LPL Financial's TGTX Position: Q2 2026 in Review

LPL Financial increased its TG Therapeutics (TGTX) stake by 44% in Q2 2026, buying an estimated $1.68M and bringing the position to 135,546 shares worth $7.45M. The position accounts for ﹤0.01% of the portfolio, ranked #2425.

LPL Financial first reported a position in TGTX in Q4 2018 and has held it in 31 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • LPL Financial held 135,546 shares of TG Therapeutics worth $7.45M as of Q2 2026.
  • LPL Financial bought 41,120 TG Therapeutics shares in Q2 2026, an estimated $1.68M.
  • TG Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #2425 holding.
  • LPL Financial first reported a position in TG Therapeutics in Q4 2018 and has held it in 31 quarters since.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.